Table 4 Outcome of patients according PD-L1 expression patterns
N = 50 | 5-Year disease-free survival (DFS) | P value | 5-Year disease-specific survival (DSS) | P value |
|---|---|---|---|---|
Tumor PD-L1 (+) (≥ 1%) | 47.7% | 0.90 | 51.4% | 0.877 |
Tumor PD-L1 (−) | 44.6% | 50.9% | ||
Tumor PD-L1(+) (≥ 5%) | 54.7% | 0.55 | 61.1% | 0.258 |
Tumor PD-L1(−) | 40.9% | 44.4% | ||
Tumor PD-L1 (+) (≥ 10%) | 67.3 | 0.095 | 67.3% | 0.085 |
Tumor PD-L1 (−) | 37.5 | 44.2% | ||
Tumor PD-L1 (+) (≥ 20%) | 83.3% | 0.041 | 83.3% | 0.049 |
Tumor PD-L1 (−) | 39.8% | 45.1% | ||
Lymphocyte PD-L1 (+) (≥ 1%) | 56.6% | 0.471 | 60.0% | 0.292 |
Lymphocyte PD-L1 (−) | 37.7% | 42.7% | ||
Lymphocyte PD-L1 (+) (≥ 5%) | 60.6% | 0.310 | 60.3% | 0.323 |
Lymphocyte PD-L1 (−) | 35.8% | 44.7% | ||
Lymphocyte PD-L1 (+) (≥ 10%) | 65.2% | 0.263 | 65.2% | 0.277 |
Lymphocyte PD-L1 (−) | 38.7% | 45.6% | ||
Lymphocyte PD-L1 (+) (≥ 20%) | 66.7% | 0.349 | 66.7% | 0.249 |
Lymphocyte PD-L1 (−) | 42.5% | 48.6% | ||
Tumor and lymphocyte PD-L1 (+) (≥ 1%) | 47.9% | 0.959 | 51.1% | 0.838 |
Tumor and lymphocyte PD-L1 (−) | 43.8% | 51.6% | ||
High tumor and lymphocyte PD-L1 (+) (≥ 5%) | 59.8% | 0.260 | 64.0% | 0.108 |
High tumor and lymphocyte PD-L1 (−) | 33.7% | 38.6% | ||
High tumor and lymphocyte PD-L1 (+) (≥ 10%) | 67.0% | 0.098 | 67.0% | 0.119 |
High tumor and lymphocyte PD-L1 (−) | 33.5% | 41.3% | ||
High tumor and lymphocyte PD-L1 (+) (≥ 20%) | 66.7% | 0.188 | 66.7% | 0.144 |
High tumor and lymphocyte PD-L1 (−) | 40.5% | 46.8% |